Skip to main content
Ningbo Menovo Pharmaceutical Co., Ltd. logo

Ningbo Menovo Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 603538 ISIN · CNE100002Y25 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,681 across all filing types
Latest filing 2026-05-26 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603538

About Ningbo Menovo Pharmaceutical Co., Ltd.

https://www.menovopharm.com/

Ningbo Menovo Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of active pharmaceutical ingredients (APIs), advanced intermediates, and finished dosage forms. The company focuses on several key therapeutic areas, including cardiovascular, central nervous system, gastrointestinal, and antiviral treatments. Its product portfolio features high-demand substances such as sartans (Valsartan, Losartan), statins (Rosuvastatin, Atorvastatin), and specialized medications like Perindopril and Entacapone. Operating with a strong emphasis on quality management and regulatory compliance, the firm provides comprehensive CDMO services to global pharmaceutical partners. By integrating its R&D capabilities with large-scale production facilities, the company maintains a significant presence in international markets, ensuring a stable supply of high-quality medicinal components and formulations.

Recent filings

Filing Released Lang Actions
宁波美诺华药业股份有限公司股票交易异常波动公告
Regulatory Filings Classification · 85% confidence The document is a Chinese corporate announcement regarding abnormal fluctuations in the company’s stock price and the company’s compliance statements in accordance with exchange rules. It does not present financial statements, voting results, or specific report content, nor does it enact a management change or dividend notice. It is a general regulatory disclosure announcement about stock trading conditions, fitting the ‘Regulatory Filings’ fallback category.
2026-05-26 Chinese
上海市广发律师事务所关于宁波美诺华药业股份有限公司2024年限制性股票激励计划首次授予第二个限售期及预留授予第一个限售期解除限售条件成就的法律意见
Regulatory Filings Classification · 90% confidence The document is a formal legal opinion letter issued by a law firm regarding the release of lock-up conditions under a 2024 restricted stock incentive plan. It is not a financial report (e.g., Annual, Interim, Earnings Release), nor a management change, dividend notice, proxy statement, M&A filing, or capital issuance announcement. Instead, it is a compliance/legal submission to the stock exchange as required under securities regulations. Therefore, it best fits the “Regulatory Filings” category (RNS).
2026-05-25 Chinese
宁波美诺华药业股份有限公司第五届董事会第二十七次会议决议公告
Regulatory Filings Classification · 78% confidence The document is an announcement of board meeting resolutions at Ningbo Meinova Pharmaceutical Co., Ltd. It does not present full financial statements (so it is not an annual or interim report), nor does it announce a change in board membership or senior management. It also is not an earnings release or dividend notice. Instead, it is a miscellaneous regulatory announcement detailing the board’s decisions (resolutions) on the equity incentive plan. This falls under general regulatory filings that don’t fit other categories.
2026-05-25 Chinese
宁波美诺华药业股份有限公司关于2024年限制性股票激励计划首次授予第二个解除限售条件及预留授予第一个解除限售条件成就的公告
Share Issue/Capital Change Classification · 80% confidence The document is a corporate announcement detailing the vesting (解除限售) of restricted stock under the company’s 2024 equity incentive plan, essentially informing stakeholders about the release of shares for circulation and related share capital adjustments. This fits the “Share Issue/Capital Change” category (SHA) rather than an annual report, earnings release, or insider dealing note. It is not a repurchase-only notice (POS) nor a simple publication announcement (RPA), but a substantive update on the company’s equity plan and resulting capital change.
2026-05-25 Chinese
宁波美诺华药业股份有限公司2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 97% confidence The document is the official announcement of resolutions and detailed voting results from Ningbo Meinovate’s 2025 Annual General Meeting, including vote counts and percentages for each proposal. This matches the definition for Declaration of Voting Results & Voting Rights Announcements, as it reports shareholder vote outcomes at the AGM.
2026-05-18 Chinese
上海市广发律师事务所关于宁波美诺华药业股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 90% confidence The document is a lawyer’s legal opinion letter (法律意见书) regarding the convening, procedures, and legality of the 2025 annual shareholders’ meeting, with detailed voting results. It is not the company’s own meeting notice or formal voting results announcement but a legal attestation by counsel. It contains no financial statements or substantive management commentary, nor is it an earnings release or annual/interim report. Under the Certification Rule, such a standalone legal opinion or certification letter is classified as a general regulatory filing. Therefore, the correct classification is Regulatory Filings (RNS).
2026-05-18 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.